Dallas, TX, June 08, 2014 --(PR.com
)-- AveXis, a clinical stage synthetic biology platform company, today announced that Dr. Allan Kaspar, Chief Scientific Officer, will be presenting at The Family and Researcher Poster Session at The Annual Spinal Muscular Atrophy Conference, which will be held on Thursday, June 12, 2014 in National Harbor, Maryland. The session will take place from 4-6 p.m. in the Prince George Exhibit Hall E at the Gaylord National Resort and Conference Center. The Family and Researcher Poster Session will allow for one-on-one interactions between families and researchers at the conference. Over thirty posters will be presented during the session. Registration for the conference is required.
About Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
Based in Dallas, Texas, AveXis is a clinical stage synthetic biology platform company establishing unique industry alliances to create innovative treatments for people with unmet medical needs. Spinal muscular atrophy (SMA) is the company’s first focus. For more information regarding AveXis, please visit www.avexisinc.com